drugset / Trial / NCT03961295

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961295

Phase 1 Completed 24 enrolled Takeda
RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to compare PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.

Timeline

Start
2018-02-22
Primary completion
2018-07-14
Completion
2018-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Vedolizumab Monoclonal antibody 108 mg Subcutaneous

Indications

No indication recorded.